Phase 1 N=85 Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers
Parkinson
Primary: Cmax - Maximum Observed Plasma Concentration — 107.3; 95.5; 424.5; 471.0 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=52 Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
Parkinson Disease
Primary: Cmax - Maximum Plasma Concentration — 985; 1245; 1200; 944 ng/mL
Phase 1 N=36 Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment
Hepatitis C
Primary: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Daclatasvir — 11215.264; 21261.199; 24789.951; 21946.450…
Phase 1 N=30 A Study of IXAZOMIB in Adult Patients With Lymphoma
Lymphoma
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 1; 1; 1; 1 participants
Phase 1 N=24 A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers
Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers
Primary: Safety - Adverse Events — 1; 1; 0; 2 Participants
Phase 1 N=54 To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
Solid Tumours
Primary: Change From Baseline in QTcF — 2.0; -4.1; -4.2 msec
Phase 1 N=22 Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide
Parkinson's Disease (PD)
Primary: Cmax - Maximum Observed Plasma Concentration of Levodopa — 314; 266; 263; 260 ng/mL
Phase 1 N=32 To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
Solid Tumors
Primary: AUC (0 to Infinity) of Total Selumetinib — 2300; 4300; 1680; 2680 ng*h/mL
Phase 1 N=17 Repetitive Transcranial Magnetic Stimulation for the Treatment of Focal Hand Dystonia
Dystonia, Focal, Task-specific
Primary: Cortical Silent Period — 9; 1.61 milliseconds
Phase 1 N=57 A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease
Parkinson's Disease
Primary: Change in Average Adhesiveness Score of 2 Days of 24 Hours Patch Application as Rated by the Investigator (or Designee) Assessed According to the EMA Draft Guideline…
Phase 1 N=18 Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects
Hyperphosphatemia · Chronic Kidney Disease
Primary: AUC0-t of Candesartan — 1118; 826; 494; 759 ng*hr/mL
Phase 1 N=19 Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects
Schizophrenia · Psychiatric Disorders
Primary: Unbound Area Under the Concentration (AUC) Time Curve Calculated to the Last Observable Concentration Brexpiprazole (AUCt,u). — 8.17; 13.3 nanograms*hours/mL (ng*h/mL)
Phase 1 N=218 Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
Schizophrenia · Schizoaffective Disorder
Primary: Time-matched QTcI Change From Baseline (Day -1) Corrected for Placebo on Day 11 Following Brexpiprazole Treatment. — 9.2; -0.2; 2.6; 9.4 msec
Phase 1 N=16 A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)
Diabetes Mellitus, Type 2
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Hour 0 to Infinity (AUC0-∞) — 23.3; 24.9 µM*hr
Phase 1 N=74 A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Neoplasms · Lymphoma, Non-Hodgkin
Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 0; 2; 0 participants